Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...